NCT05401318 Tailoring Treatment in Colorectal Cancer
| NCT ID | NCT05401318 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Akershus |
| Condition | Colorectal Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2022-03-28 |
| Primary Completion | 2025-03-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2022-03-28 with a primary completion date of 2025-03-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, the investigators will establish a reliable method and logistic pipeline for personalized drug testing ex vivo using fresh tumor samples from colorectal cancer (CRC) patients. With this, the investigators aim to develop a novel predictive biomarker of immunotherapy response, by testing combinations of chemotherapies and chimeric antigen receptor (CAR) T cells. Critically, this affects a large subgroup of patients currently not considered to benefit from such treatment. To support the hypothesis, the project will make use of cutting-edge, cell-based functional diagnostics. Individual patients' cancer cells will be screened against a panel of chemotherapies and targeted therapies including CAR T cells, to assess the optimal combination of therapies to induce immunotherapy efficacy in otherwise unresponsive CRC.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed colorectal cancer scheduled for curative surgery and standard clinical follow-up. Exclusion Criteria: \- Unable/unwilling to sign the informed consent form.
Contact & Investigator
Sebastian Meltzer, M.D., Ph.D.
PRINCIPAL INVESTIGATOR
University Hospital, Akershus
Frequently Asked Questions
Who can join the NCT05401318 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05401318 currently recruiting?
Yes, NCT05401318 is actively recruiting participants. Contact the research team at sebastian.meltzer@medisin.uio.no for enrollment information.
Where is the NCT05401318 trial being conducted?
This trial is being conducted at Lørenskog, Norway.
Who is sponsoring the NCT05401318 clinical trial?
NCT05401318 is sponsored by University Hospital, Akershus. The principal investigator is Sebastian Meltzer, M.D., Ph.D. at University Hospital, Akershus. The trial plans to enroll 40 participants.